AKASA
We're Hiring!
AKASA Company Growth, Stability & Outlook
What People Are Saying About AKASA
-
Investor Backing & Capital Strength: A $120M Series C closed in June 2024 signals expansion runway and resources to scale. Continued awards and commercial activity through 2026 reinforce the availability of capital to support growth initiatives.
-
Strategic Partnerships: Cleveland Clinic announced a strategic collaboration in April 2025 and deepened it to a system‑wide rollout in October 2025, indicating enterprise‑level adoption and expansion. Named outcomes like Nebraska Methodist’s reported $2M+ gross revenue uplift further support partner confidence and real‑world impact.
-
Product Line Growth: A steady cadence of launches—such as medical coding (June 2024) and CDI Optimizer (May 2025)—broadens mid‑revenue‑cycle coverage and cross‑sell potential. Active presence at industry events and recognitions in 2026 align with ongoing momentum behind the expanding product suite.
